Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178145 | 0.86 | SIGMAR1 (0.68) | SIGMAR1HTR2AHTR2CHTR2BPIN1 | |
| SCHEMBL30881187 | 0.80 | CYP1A1 (0.43) | SIGMAR1PIN1 | |
| SCHEMBL30881190 | 0.80 | CYP1A1 (0.43) | SIGMAR1PIN1 | |
| SCHEMBL5349498 | 0.77 | SIGMAR1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL30185870 | 0.77 | SIGMAR1 (0.70) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3546367 | 0.76 | L3MBTL1 (0.58) | KDM4ELMNA | |
| SCHEMBL6178711 | 0.76 | CCR8 (0.54) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23232573 | 0.76 | HTR2A (0.52) | HTR2AHTR2CHTR2BPIN1KDM4E | |
| SCHEMBL30741563 | 0.76 | HTR2A (0.52) | HTR2AHTR2CHTR2BPIN1KDM4E | |
| SCHEMBL7542807 | 0.75 | SIGMAR1 (0.72) | SIGMAR1OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210971-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-9944596-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-3210971-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233339-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RARA | SIGMAR1 4616/4885HTR2A 4306/4885HTR2C 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.